S-Adenosyl-L-homocysteine (SAH), a potent methyltransferase inhibitor and a substrate of the s-adenosylhomocysteine hydrolase, is an amino acid derivative and an intermediator or modulator of several metabolic pathways, including the activated methyl cycle and cysteine biosynthesis. It was shown, that the plasma SAH might be a novel biomarker for the early clinical identification of cardiovascular disease. In addition, the elevated SAH in Alzheimer's brain was related to markers of disease progression and cognitive impairment.

L-Norpseudoephedrine is a psychostimulant drug of amphetamine family, first isolated from an Ephedra species. It is one of the two enantiomers of norpseudoephedrine, less potent that D-Norpseudoephedrine. L-Norpseudoephedrine is a norepinephrine and dopamine releasing agent, and has thermogenic and anorectic effect.

L-838,417 is a subtype-selective GABAA modulator, acting as a partial agonist at alpha2, alpha3 and alpha5 subtypes and an antagonist at the alpha1 subtype. L-838,417 displays anxiolytic effects in vivo and is used as a tool compound to study roles of GABAA subunits.

L-368,899 is a potent and selective oxytocin (OT) receptor antagonist, which was developed by Merc as a promising non peptide OT antagonist. However, this compound failed in clinical development; phase II, for the treatment of premature labour. Merck subsequently abandoned its non peptide OT antagonist program.